 Eid Parry IndiaOther Food Products | Q1 FY27 Results: Standalone Loss Widens to Rs 89 Crore12 Aug 2026Pat NegativeRevenue DeclineEbitda Margin Compression | -0.1% — — | ₹798 | 14,196 Cr | — | 13.1% | -32.2% |
 JK Tyre & IndustriesTyres & Rubber Products | JK Tyre Q1 FY27 results: Revenue down 6.6%, PAT plunges 76% YoY7 Aug 2026Revenue DeclinePat NegativeEbitda Margin Compression | -6.8% -7.4% — | ₹375 | 10,668 Cr | 13.8vs 24.1 | 9.9% | +5.3% |
 Signatureglobal IndiaResidential Commercial Projects | Signatureglobal Q1FY27: Revenue drops 37% YoY, swings to loss6 Aug 2026Revenue DeclinePat NegativeEbitda Margin Compression×2 | +2.0% -0.4% — | ₹793 | 11,142 Cr | 11.0vs 22.3 | 34.7% | +227.1% |
 Cohance LifesciencesPharmaceuticals | Q1FY27: Revenue falls 23%, PAT turns negative on weak CDMO and NJ Bio losses5 Aug 2026Revenue DeclinePat NegativeEbitda Margin Compression | +4.2% +4.3% — | ₹462 | 17,690 Cr | 157.3vs 28.5 | 4.1% | -44.0% |
 Nazara TechnologiesDigital Entertainment | Nazara Q1 FY27: Rs 82 Cr loss, revenue dips 14%, new CEO from Sept3 Aug 2026Revenue DeclinePat NegativeEbitda Margin Compression | +2.4% +5.0% — | ₹354 | 13,116 Cr | 368.8 | 8.6% | -24.4% |
 Indo Count IndustriesOther Textile Products | Indo Count Industries Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.30 May 2026Pat NegativeEbitda Margin CompressionRevenue Decline | +9.8% +3.4% +38.4% | ₹441 | 8,742 Cr | 89.7vs 15.3 | 5.4% | -0.4% |
 Jupiter WagonsRailway Wagons | Jupiter Wagons Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.30 May 2026Revenue DeclinePat NegativeEbitda Margin Compression | -1.6% -6.8% -7.9% | ₹247 | 10,554 Cr | 55.7 | 7.6% | -0.7% |
 Jai Balaji IndustriesJAIBALAJI | Consideration and approval of the Audited Financial Results of the Company for the fourth quarter and year ended 31st March, 2026, amongst other items of agenda.30 May 2026Revenue DeclinePat NegativeEbitda Margin Compression | -3.2% -9.6% -5.3% | ₹64.4 | 5,875 Cr | 30.4 | 5.7% | -14.9% |
 Swan CorpPetrochemicals | Outcome of Board Meeting held on 29th May, 2026.29 May 2026Revenue DeclinePat NegativeEbitda Margin Compression | -3.9% -5.4% -4.4% | ₹304 | 9,518 Cr | 19.0vs 20.6 | 3.3% | -23.6% |
 Concord BiotechPharmaceuticals | Outcome of Board Meeting held today i.e. Friday, May 29, 2026 wherein the Board inter-alia considered and approved Audited Financial results and statements for the Financial Year ended ....29 May 2026Revenue DeclinePat NegativeEbitda Margin Compression | +12.3% +25.6% +22.5% | ₹1,560 | 16,320 Cr | 58.5vs 28.5 | 16.5% | +32.0% |
 Natco PharmaPharmaceuticals | Audited Financial Results for the quarter and year ended 31st March, 202629 May 2026Revenue DeclinePat NegativeEbitda Margin Compression×2 | -20.7% -26.4% -22.1% | ₹883 | 15,799 Cr | 18.8vs 28.5 | 15.9% | -45.8% |
 Tega IndustriesIndustrial Products | Tega Industries Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.29 May 2026Pat NegativeEbitda Margin CompressionRevenue Decline | +12.7% +12.2% +5.9% | ₹1,748 | 13,132 Cr | 102.7vs 23.8 | 5.4% | +30.0% |
 Deepak Fertilizers & PetrCommodity Chemicals | Statement of Audited Standalone and Consolidated Financial results for the quarter and year ended 31st March, 202628 May 2026Pat NegativeRevenue DeclineEbitda Margin Compression×2 | -3.5% +4.9% +6.6% | ₹1,448 | 18,280 Cr | 32.5vs 17.5 | 8.4% | +0.2% |
 Morepen Lab.Pharmaceuticals | Morepen Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.26 May 2026Revenue DeclinePat NegativeEbitda Margin Compression | -2.5% -3.6% +23.8% | ₹95.7 | 5,244 Cr | 61.4vs 28.5 | 8.3% | +17.8% |
